Arcus, and he has a patent filed by his institution related to the use of tumor mutation burden to predict response to immunotherapy (PCT/US2015/062208), which has received licensing fees from PGDx. R. Korn serves as CMIO of ImaginAb. A. Mascioni is employed by ImaginAb. W. Le serves as VP of Operations at ImaginAb. I. Wilson serves as CEO of ImaginAb. M. Gordon receives consulting fees from ImaginAb and Imaging Endpoints. A. Wu receives consulting fees from ImaginAb. G. Ulaner receives consulting fees from ImaginAb and is a member of the Scientific Advisory Board for ImaginAb. J. Wolchock has equity in Tizona Pharmaceuticals, Adaptive Biotechnologies, Imvaq, Beigene, Linneaus, Apricity, Arsenal IO, and Georgiamune. M. Postow receives grant/research support from ImaginAb. N. Pandit-Taskar has served as a consultant for or been on an advisory board and has received honoraria for ImaginAb, and receives grant/research support from ImaginAb. No other potential conflict of interest relevant to this article was reported.